Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.30 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894791 | 0.77 | PDE10A (0.36) | PDE10AERN1ALDH1A1HTTKDM4E | |
| Hydrochloric Acid SCHEMBL5439722 | 0.74 | PDE10A (0.34) | PDE10AERN1ALDH1A1HTTKDM4E | |
| SCHEMBL102290 | 0.73 | PDE10A (0.34) | PDE10APDE2ARAB9ASMN1; SMN2 | |
| SCHEMBL30885822 | 0.73 | — | — | |
| SCHEMBL30971771 | 0.72 | ALOX15 (0.53) | ALDH1A1HTTKDM4EHPGDRAB9A | |
| SCHEMBL6870350 | 0.72 | ALOX15 (0.53) | ALDH1A1HTTKDM4EHPGDRAB9A | |
| SCHEMBL35211324 | 0.71 | — | — | |
| SCHEMBL24402037 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL4928225 | 0.70 | ALOX15 (0.50) | ALDH1A1HTTKDM4EHPGDRAB9A | |
| SCHEMBL4777776 | 0.70 | KDM4E (0.44) | ALDH1A1KDM4EHPGDHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | PDE10A 898/4885PDE2A 845/4885ERN1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.